Sign up to access all valuation multiples
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.
2016
n/a
LTM Revenue $296M
LTM EBITDA $23.0M
$4.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of January 2026, BillionToOne reported last 12-month revenue of $296M and EBITDA of $23.0M.
In the same period, BillionToOne generated $198M in LTM gross profit and $2.2M in net income.
See BillionToOne valuation multiples based on analyst estimatesIn the most recent fiscal year, BillionToOne reported revenue of $153M and EBITDA of -$27.5M.
BillionToOne expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BillionToOne valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $296M | XXX | $153M | XXX | XXX | XXX |
| Gross Profit | $198M | XXX | $80.9M | XXX | XXX | XXX |
| Gross Margin | 67% | XXX | 53% | XXX | XXX | XXX |
| EBITDA | $23.0M | XXX | -$27.5M | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | -18% | XXX | XXX | XXX |
| EBIT | $8.2M | XXX | -$47.1M | XXX | XXX | XXX |
| EBIT Margin | 3% | XXX | -31% | XXX | XXX | XXX |
| Net Profit | $2.2M | XXX | -$41.6M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | -27% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BillionToOne has current market cap of $4.1B, and EV of $4.0B.
As of February 20, 2026, BillionToOne's stock price is $89.
See BillionToOne trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.0B | $4.1B | XXX | XXX | XXX | XXX | $0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialBillionToOne's trades at 13.5x EV/Revenue multiple, and 173.3x EV/EBITDA.
See valuation multiples for BillionToOne and 15K+ public compsAs of February 20, 2026, BillionToOne has market cap of $4.1B and EV of $4.0B.
Equity research analysts estimate BillionToOne's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BillionToOne has a P/E ratio of 1884.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.1B | XXX | $4.1B | XXX | XXX | XXX |
| EV (current) | $4.0B | XXX | $4.0B | XXX | XXX | XXX |
| EV/Revenue | 13.5x | XXX | 13.5x | XXX | XXX | XXX |
| EV/EBITDA | 173.3x | XXX | 173.3x | XXX | XXX | XXX |
| EV/EBIT | 485.5x | XXX | 485.5x | XXX | XXX | XXX |
| EV/Gross Profit | 20.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 1884.9x | XXX | -98.1x | XXX | XXX | XXX |
| EV/FCF | 9979.7x | XXX | 9979.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBillionToOne's last 12 month revenue growth is 36%
BillionToOne's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
BillionToOne's rule of 40 is -66% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BillionToOne's rule of X is 97% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BillionToOne and other 15K+ public comps| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 36% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | 31% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -66% | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 97% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 84% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mirxes Holding Co | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BillionToOne acquired XXX companies to date.
Last acquisition by BillionToOne was XXXXXXXX, XXXXX XXXXX XXXXXX . BillionToOne acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was BillionToOne founded? | BillionToOne was founded in 2016. |
| Where is BillionToOne headquartered? | BillionToOne is headquartered in United States of America. |
| Who is the CEO of BillionToOne? | BillionToOne's CEO is Dr. Oguzhan Atay, PhD. |
| Is BillionToOne publicy listed? | Yes, BillionToOne is a public company listed on NAS. |
| What is the stock symbol of BillionToOne? | BillionToOne trades under BLLN ticker. |
| When did BillionToOne go public? | BillionToOne went public in 2025. |
| Who are competitors of BillionToOne? | Similar companies to BillionToOne include e.g. EZZ Life Science, Epigenomics, Mirxes Holding Co, ToolGen. |
| What is the current market cap of BillionToOne? | BillionToOne's current market cap is $4.1B |
| What is the current revenue of BillionToOne? | BillionToOne's last 12 months revenue is $296M. |
| What is the current revenue growth of BillionToOne? | BillionToOne revenue growth (NTM/LTM) is 36%. |
| What is the current EV/Revenue multiple of BillionToOne? | Current revenue multiple of BillionToOne is 13.5x. |
| Is BillionToOne profitable? | Yes, BillionToOne is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BillionToOne? | BillionToOne's last 12 months EBITDA is $23.0M. |
| What is BillionToOne's EBITDA margin? | BillionToOne's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of BillionToOne? | Current EBITDA multiple of BillionToOne is 173.3x. |
| What is the current FCF of BillionToOne? | BillionToOne's last 12 months FCF is $0.4M. |
| What is BillionToOne's FCF margin? | BillionToOne's last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of BillionToOne? | Current FCF multiple of BillionToOne is 9979.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
